fda warning letters compounded semaglutide september 2025 Warns Novo Nordisk on Unreported Deaths FDA Drug Recalls and Warnings:

Fewer side effects: While most weight loss medications come with gastrointestinal side effects like nausea and diarrhea, the dual effect of GLP-1 and GIP means these side effects may be less severe with tirzepatide than alternatives like semaglutide

It is important to realise that the doses for retatrutide are not fixed and will need further studies to confirm the doses and dosing schedule

Our experience led to a proof-of-concept study in the insulin-secreting pancreatic -cell line, MIN-6, and the GLP-1-secreting intestinal L-cell line, GLUTag

The tissue needs time to recover fully

Following this, there have been two clinical phase 2 trials (SAR425899 and MEDI0382 also known as cotadutide) published evaluating GLP-1/glucagon receptor co-agonists